December 29, 2025 11:11 am (IST)

Make this your homepage

All Finance

CBI moves Supreme Court challenging Kuldeep Sengar's relief in Unnao rape case | Music under attack: Islamist mob attacks James concert with bricks, stones in Bangladesh, dozens hurt | Christmas vandalism sparks mass arrests in Raipur; Assam acts too with crackdown on 'religious intolerance' | BJP's VV Rajesh becomes Thiruvananthapuram Mayor after party topples Left's 45-year-rule in city corporation | ‘I can’t bear the pain’: Indian-origin father of three dies after 8-hour hospital wait in Canada hospital | Janhvi Kapoor, Kajal Aggarwal, Jaya Prada slam brutal lynching in Bangladesh, call out ‘selective outrage’ | Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion

Aurobindo Pharma receives USFDA approval for drug related to moderate dementia

India Blooms News Service | | Mar 29, 2016, at 08:16 pm

#Aurobindo Pharma receives USFDA # US Food & Drug Administration

Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.

This product is expected to be launched in the first quarter of fiscal year 2016-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.

Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease.

The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.

This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products.

Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am

In Images: Glimpses from Bengali film Fatafati's premiere May 13, 2023, at 08:39 pm